Поиск по международным и национальным патентным фондам
Некоторое содержание этого приложения в настоящий момент недоступно.
Если эта ситуация сохраняется, свяжитесь с нами по адресуОтзывы и контакты
1. (WO2019046659) COMPOSITION FOR AND METHOD TO INCREASE SERUM ADIPONECTIN AND REDUCE BODY FAT
Примечание: Текст, основанный на автоматизированных процессах оптического распознавания знаков. Для юридических целей просьба использовать вариант в формате PDF

CLAIMS

1. A method for treating a subject, comprising:

administering to a subject an amount of a composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid, which amount is effective for treating and/or reducing the risk of obesity in the subject.

2. The method of claim 1, wherein the treating and/or reducing of the risk of obesity in the subject comprises decreasing the percentage of body fat, reducing body mass, and/or reducing waist circumference of the subject.

3. The method of claim 1, wherein the treating and/or reducing of the risk of obesity in the subject comprises increasing adiponectin levels in the subject.

4. The method of any one of claims 1-3, wherein the amount is administered to the subject at least once per day.

5. The method of claim 4, wherein the amount that is administered to the subj ect at least once per day is about 0.50 to about 10.00 grams.

6. The method of any one of claims 1-3, wherein the amount is administered to the subject over a period of at least four weeks.

7. The method of any one of claims 1-3, wherein the amount is administered to the subject over a period of at least eight weeks.

8. The method any one of claims 1-3, wherein increasing adiponectin levels in the subject comprises increasing the level of adiponectin in the plasma and/or blood of the subject by around 40 to 60 percent after around 4 weeks of treatment.

9. The method of any one of claims 1-3, wherein increasing adiponectin levels in the subject comprises increasing the level of adiponectin in the plasma and/or blood of the subject by around 100 to 125 percent after around 8 weeks of treatment.

10. The method of any one of claims 1-3, wherein the composition is administered to the subject in an oral formulation.

11. The method of claim 10, wherein the oral formulation has a minimum viscosity of about 5,000 cps.

12. The method of any one of claims 1-3, wherein decreasing the percentage of body fat, reducing body mass, and/or reducing waist circumference of the subject comprises reducing the percentage of body fat, body mass, and/or waist circumference of the subject by around 1 percent to 10 percent after 4 weeks of treatment.

13. The method of any one of claims 1-3, wherein decreasing the percentage of body fat, reducing body mass, and/or reducing waist circumference of the subject of the subject comprises reducing the percentage of body fat, body mass, and/or waist circumference of the subject by around 10 to 20 percent after 8 weeks of treatment.

14. The method of any one of claims 1-3, wherein the composition is consumed with a drink, shake, and/or mixed with food.

15. The method of claim 14, wherein the Hydroxypropyl Methyl Cellulose comprises a blend of Hydroxypropyl Methyl Cellulose having at least three different molecular weights and/or viscosity levels.

16. The method of claim 15, wherein the blend comprises K15, K100, and K200 Hydroxypropyl Methyl Cellulose.

17. The method of claim 15, wherein the blend has a viscosity range between 5,000 cps and 150,000 cps.

18. The method of any one of claims 1-3, wherein the myristic fatty acid is present in the composition at 0.1 % to 10% w/w.

19. A method for treating a subject, comprising:

administering to a subject an amount of a composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid, which amount is effective for treating and/or reducing the risk of obesity in the subject;

wherein the treating and/or reducing of the risk of obesity in the subject comprises decreasing the percentage of body fat, reducing body mass, and/or reducing waist circumference of the subject;

wherein the Hydroxypropyl Methyl Cellulose comprises a blend of Hydroxypropyl Methyl Cellulose having at least three different viscosity levels which provide a viscosity range between 5,000 cps and 100,000 cps; and

wherein the myristic fatty acid is present in the composition at 0.1 % to 10% w/w.

20. The method of claim 19, wherein the treating and/or reducing of the risk of obesity in the subject further comprises increasing adiponectin levels in the subject.

21. A composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid.

22. The composition of claim 21, wherein the Hydroxypropyl Methyl Cellulose comprises a blend of Hydroxypropyl Methyl Cellulose having at least three different molecular weights and/or viscosity levels.

23. The composition of claim 22, wherein the blend comprises K15, K100, and K200 Hydroxypropyl Methyl Cellulose.

24. The composition of claim 22, wherein the blend has an average viscosity level of between 25,000 cps and 75,000 cps.

25. The composition of any one of claims 21-24, wherein the composition comprises about 30 to about 60 weight percent K15 Hydroxypropyl Methyl Cellulose.

26. The composition of any one of claims 21-24, wherein the composition comprises about 20 to about 60 weight percent K100 Hydroxypropyl Methyl Cellulose.

27. The composition of any one of claims 21-24, wherein the composition comprises about 5 to about 25 weight percent K200 Hydroxypropyl Methyl Cellulose.

28. The composition of any one of claims 21-24, wherein the myristic fatty acid is present in the composition at 0.1 % to 10 % w/w.

29. The composition of any one of claims 21-24, wherein the myristic fatty acid is present in the composition at 1 % to 5 % w/w.

30. A composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid; wherein the Hydroxypropyl Methyl Cellulose comprises a blend of Hydroxypropyl Methyl

Cellulose having at least two different molecular weights and/or viscosity levels which provide an average viscosity level to the composition of between 25,000 cps and 75,000 cps; and

wherein the myristic fatty acid is present in the composition at 0.1 % to 10% w/w.

31. Use of a composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid to treat or reduce the risk of obesity in a subject.

32. Use of the composition of claim 31, wherein the Hydroxypropyl Methyl Cellulose comprises a blend of Hydroxypropyl Methyl Cellulose having at least three different molecular weights and/or viscosity levels.

33. Use of the composition of claim 31, wherein the blend comprises K15, K100, and K200 Hydroxypropyl Methyl Cellulose.

34. Use of the composition of claim 31, wherein the blend has an average viscosity level of between 25,000 cps and 75,000 cps.

35. Use of the composition of any one of claims 31-34, wherein the composition comprises about 30 to about 60 weight percent K15 Hydroxypropyl Methyl Cellulose.

36. Use of the composition of any one of claims 31-34, wherein the composition comprises about 20 to about 60 weight percent K100 Hydroxypropyl Methyl Cellulose.

37. Use of the composition of any one of claims 31-34, wherein the composition comprises about 5 to about 25 weight percent K200 Hydroxypropyl Methyl Cellulose.

38. Use of the composition of any one of claims 31-34, wherein the myristic fatty acid is present in the composition at 0.1 % to 10 % w/w.

39. Use of the composition of any one of claims 31-34, wherein the myristic fatty acid is present in the composition at 1 % to 5 % w/w.

40. Use of a composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid to treat or reduce the risk of obesity in a subject;

wherein the Hydroxypropyl Methyl Cellulose comprises a blend of Hydroxypropyl Methyl Cellulose having at least two different molecular weights and/or viscosity levels which provide an average viscosity level to the composition of between 25,000 cps and 75,000 cps; and

wherein the myristic fatty acid is present in the composition at 0.1 % to 10% w/w.

41. Use of a composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid for the manufacture of a medicament for treating and/or reducing the risk of obesity in a subject.

42. A composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid for use in a method of treating a subject comprising:

administering to the subject an amount of a composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid, which amount is effective for treating or reducing the risk of obesity in the subject.

43. The composition for use according to claim 42, wherein the treating and/or reducing of the risk of obesity in the subject comprises decreasing the percentage of body fat, reducing body mass, and/or reducing waist circumference of the subject.

44. The composition for use according to claim 42, wherein the treating and/or reducing of the risk of obesity in the subject comprises increasing adiponectin levels in the subject.

45. The composition for use according to any one of claims 42-44, wherein the amount is administered to the subject at least once per day.

46. The composition for use according to any one of claims 42-44, wherein the amount that is administered to the subject at least once per day is about 0.50 to about 10.00 grams.

47. The composition for use according to any one of claims 42-44, wherein the amount is administered to the subject over a period of at least four weeks.

48. The composition for use according to any one of claims 42-44, wherein the amount is administered to the subject over a period of at least eight weeks.

49. The composition for use according to any one of claim 44, wherein increasing adiponectin levels in the subject comprises increasing the level of adiponectin in the plasma and/or blood of the subject by around 40 to 60 percent after around 4 weeks of treatment.

50. The composition for use according to any one of claim 44, wherein increasing adiponectin levels in the subject comprises increasing the level of adiponectin in the plasma and/or blood of the subject by around 100 to 125 percent after around 8 weeks of treatment.

51. The composition for use according to any one of claims 42-44, wherein the composition is administered to the subject in an oral formulation.

52. The composition for use according to claim 51, wherein the oral formulation has a minimum viscosity of about 5,000 cps.

53. The composition for use according to any one of claims 42-44, wherein decreasing the percentage of body fat, reducing body mass, and/or reducing waist circumference of the subject comprises reducing the percentage of body fat, body mass, and/or waist circumference of the subject by around 1 to 10 percent after 4 weeks of treatment.

54. The composition for use according to any one of claims 42-44, wherein decreasing the percentage of body fat, reducing body mass, and/or reducing waist circumference of the subject comprises reducing the percentage of body fat, body mass, and/or waist circumference of the subject by around 10 to 20 percent after 8 weeks of treatment.

55. The composition for use according to any one of claims 42-44, wherein the composition is consumed with a drink, shake, and/or mixed with food.

56. The composition for use according to claim 55, wherein the Hydroxypropyl Methyl Cellulose comprises a blend of Hydroxypropyl Methyl Cellulose having at least three different molecular weights or viscosity levels.

57. The composition for use according to claim 56, wherein the blend comprises K15, K100, and K200 Hydroxypropyl Methyl Cellulose.

58. The composition for use according to claim 56, wherein the blend has an average viscosity level of between 25,000 cps and 75,000 cps.

59. The composition for use according to any one of claims 42-44, wherein the myristic fatty acid is present in the composition at 0.1 % to 10% w/w.

60. A composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid for use in a method of treating a subject comprising:

administering to a subject an amount of a composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid, which amount is effective for treating and/or reducing the risk of obesity in the subject;

wherein the treating and/or reducing of the risk of obesity in the subject comprises decreasing the percentage of body fat, reducing body mass, and/or reducing waist circumference of the subject;

wherein the Hydroxypropyl Methyl Cellulose comprises a blend of Hydroxypropyl Methyl Cellulose having at least three different molecular weights or viscosity levels which provide an average viscosity level to the composition of between 25,000 cps and 75,000 cps; and wherein the myristic fatty acid is present in the composition at 0.1 % to 10% w/w.

61. A composition for use in a method for treating and/or reducing the risk of obesity in a subject, the composition comprising Hydroxypropyl Methyl Cellulose and myristic fatty acid.